

FOOD AND DRUG ADMINISTRATION  
Center for Drug Evaluation and Research  
ANESTHETIC AND LIFE SUPPORT DRUGS ADVISORY COMMITTEE (ALSAC) MEETING  
Holiday Inn, Ballrooms, 2 Montgomery Village Avenue, Gaithersburg, MD

**DRAFT AGENDA**  
January 31, 2002

8:00 a.m.	Call to Order and Introductions	Nathaniel P. Katz, M.D. Acting Chair, ALSAC
	Conflict of Interest Statement	Kimberly L. Topper Executive Secretary, ALSAC
8:05 a.m.	Welcome to Second Day and Introductory Comments	Cynthia McCormick, M.D. Director, Division of Anesthetic, Critical Care and Addiction Drug Products (DACADP), FDA
8:15 a.m.	Open Public Hearing	
9:15 a.m.	Industry Presentation	J. David Haddox, M.D., D.D.S. Senior Medical Director Health Policy Purdue Pharma LP
10:05 a.m.	Introduction to Session III: Prescription Drug Abuse	Bob Rappaport, M.D. Deputy Director, DACADP, FDA
10:15 a.m.	Current Data on Abuse and Diversion	Judy Ball, Substance Abuse and Mental Health Services Administration, (SAMHSA)
10:35 a.m.	Break	
10:50 a.m.	Criminal Activity Associated with Opiate Analgesics	Drug Enforcement Administration (DEA)
11:10 a.m.	FDA Assessment of Abuse Liability	Deborah Leiderman, M.D., Director, Controlled Substance Staff, FDA
11:30 a.m.	Discussion	
11:45 a.m.	Epidemiology of Prescription Drug Abuse: Implications for the Clinical Setting	Howard Chilcoat, M.D. Johns Hopkins University
12:15 p.m.	Prescription Drug Abuse in Pain Patients	Steven Passik, M.D. Community Cancer Care Center, Inc.
12:45 p.m.	Discussion	
1:00 p.m.	Lunch	
2:00 p.m.	Regulatory Approaches to Risk Management of Prescription Opioid Drug Abuse	Sharon Hertz, M.D. Medical Officer, DACADP, FDA
2:15 p.m.	Questions and Discussion	
5:30 p.m.	Adjourn	